妊娠合并心血管病抗凝治疗概况

中国临床药理学与治疗学 ›› 2014, Vol. 19 ›› Issue (2): 223-227.

妊娠合并心血管病抗凝治疗概况

熊琴梅, 洪葵

南昌大学第二附属医院心内科,南昌 330006,江西

收稿日期:2013-03-23 修回日期:2014-02-10 出版日期:2014-02-26 发布日期:2014-03-31
通讯作者: 洪葵,女,博士,主任医师,研究方向:心血管疾病,遗传性心律失常。Tel: 0791-86312917 E-mail: hongkui88@163.com
作者简介:熊琴梅,女,博士研究生,主治医师,研究方向:心血管疾病。Tel: 0791-86312917 E-mail: xqm0711@sina.com

Survey on anticoagulant therapy in pregnant women with cardiovascular disease

XIONG Qin-mei, HONG Kui

Department of Cardiology, Second Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi, China

Received:2013-03-23 Revised:2014-02-10 Online:2014-02-26 Published:2014-03-31

摘要/Abstract

摘要： 近年来,抗凝治疗药物的广泛应用使得越来越多的患者从防治血栓栓塞事件中获益。然而,抗凝药物好比一把双刃剑,常常是风险与受益并存。如何平衡防治栓塞和出血的矛盾并优化治疗方案,始终是临床医生必须面对的一个严峻问题。除此之外,妊娠期妇女这类特殊人群的抗凝药物使用更是一个复杂且充满挑战的难题。基于近年来妊娠妇女抗凝药物治疗的临床研究,以及最新相关指南的推荐,本综述从妊娠妇女的高凝状态、主要抗凝药物种类及临床应用几方面介绍妊娠合并心血管病患者的抗凝治疗概况。

关键词: 妊娠, 心血管病, 抗凝, 华法林, 肝素

Abstract: In recent years, extensive application of anticoagulation drugs benefits more and more patients suffering from thromboembolic events. However, the anticoagulants have benefits and risks, which like a double-edged sword. How to balance the prevention of thromboembolism and the bleeding problems and optimize the treatments might be a serious problem for clinical physicians. Considering the women with pregnancy, anticoagulant therapy is a complex and challenging problem. According to the latest guidelines and recent studies on pregnant women with anticoagulant therapy, this review summarized anticoagulant therapies for the pregnant women with cardiovascular diseases, which includes the hypercoagulable states of pregnant women, the main types of anticoagulant drugs and clinical application.

Key words: pregnancy, cardiovascular disease, anticoagulation, Warfarin, Heparin

中图分类号:

R543
714.252

熊琴梅, 洪葵. 妊娠合并心血管病抗凝治疗概况[J]. 中国临床药理学与治疗学, 2014, 19(2): 223-227.

XIONG Qin-mei, HONG Kui. Survey on anticoagulant therapy in pregnant women with cardiovascular disease[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(2): 223-227.

参考文献

[1] Chen H, Zhou L, Meng L, et al. Coagulation and prothrombotic state parameters: a clinical analysis during early pregnancy[J]. Ir J Med Sci, 2011, 180(4): 813-817.
[2] Hui C, Lili M, Libin C, et al. Changes in coagulation and hemodynamics during pregnancy: a prospective longitudinal study of 58 cases[J]. Arch Gynecol Obstet, 2012, 285(5): 1231-1236.
[3] Choi JW, Pai SH. Tissue plasminogen activator levels change with plasma fibrinogen concentrations during pregnancy[J]. Ann Hematol, 2002, 81(11): 611-615.
[4] Uchikova EH, Ledjev II. Changes in haemostasis during normal pregnancy[J]. Eur J Obstet Gynecol Reprod Biol, 2005, 119(2): 185-188.
[5] Szecsi PB, Jorgensen M, Klajnbard A, et al. Haemostatic reference intervals in pregnancy[J]. Thromb Haemost, 2010, 103(4): 718-727.
[6] Wickstrom K, Edelstam G, Lowbeer CH, et al. Reference intervals for plasma levels of fibronectin, von Willebrand factor, free protein S and antithrombin during third-trimester pregnancy[J]. Scand J Clin Lab Invest, 2004, 64(1): 31-40.
[7] James AH, Jamison MG, Biswas MS, et al. Acute myocardial infarction in pregnancy: a United States population-based study[J]. Circulation, 2006, 113(12): 1564-1571.
[8] Heit JA, Kobbervig CE, James AH, et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study[J]. Ann Intern Med, 2005, 143(10): 697-706.
[9] James AH, Jamison MG, Brancazio LR, et al. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality[J]. Am J Obstet Gynecol, 2006, 194(5): 1311- 1315.
[10] Regitz-Zagrosek V, Blomstrom LC, Borghi C, et al. ESC guidelines on the management of cardiovascular diseases during pregnancy: the task force on the management of cardiovascular diseases during pregnancy of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2011, 32(24): 3147-3197.
[11] Vitale N, De Feo M, De Santo LS, et al. Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves[J]. J Am Coll Cardiol, 1999, 33(6): 1637-1641.
[12] Bian C, Wei Q, Liu X. Influence of heart-valve replacement of warfarin anticoagulant therapy on perinatal outcomes[J]. Arch Gynecol Obstet, 2012, 285(2): 347-351.
[13] Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J]. Chest, 2012, 141(2 Suppl): e691S-e736S.
[14] Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature[J]. Arch Intern Med, 2000, 160(2): 191-196.
[15] Abildgaard U, Sandset PM, Hammerstrom J, et al. Management of pregnant women with mechanical heart valve prosthesis: thromboprophylaxis with low molecular weight heparin[J]. Thromb Res, 2009, 124(3): 262-267.
[16] Hameed A, Akhter MW, Bitar F, et al. Left atrial thrombosis in pregnant women with mitral stenosis and sinus rhythm[J]. Am J Obstet Gynecol, 2005, 193(2): 501-504.
[17] Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)[J]. Europace, 2010, 12(10): 1360-1420.
[18] Healey JS, Hart RG, Pogue J, et al. Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W)[J]. Stroke, 2008, 39(5): 1482-1486.
[19] 黄晓晖,王夏芹,唐海沁,等.华法林和阿司匹林联用在大鼠体内的药代动力学研究[J].中国临床药理学与治疗学,2012,17(2):189-194.